INSTITUTO DE SAUDE PUBLICA DA UNIVERSIDADE DO PORTO

Their core work

The Institute of Public Health at the University of Porto is a research centre focused on population health, epidemiology, and lifecourse research. They specialize in large-scale cohort studies tracking how environmental exposures, social conditions, and biological pathways affect health outcomes from pregnancy through adulthood. Their work spans childhood obesity policy, tuberculosis treatment innovation, cervical cancer screening equity, and exposome science — consistently bridging epidemiological data with public health interventions. They bring strong capabilities in data management, biostatistics, and health economics to European research consortia.

What they specialise in

How they've shifted over time

In the early period (2015–2018), their work centred on classical epidemiology: large cohort studies with phenotyping and biological samples (LIFEPATH), preterm birth outcomes (RECAP), and childhood health determinants like physical activity and food consumption (STOP). From 2019 onward, they shifted toward more applied and technology-integrated health research — exposome science, pharmacogenetics, e-nose diagnostics, AI-driven clinical trial design (UNITE4TB), and FAIR data infrastructure. The trend is clear: moving from observational population studies toward intervention-ready, data-intensive public health research.

They are evolving from traditional cohort-based epidemiology toward technology-enabled health research combining exposome data, AI-driven clinical trials, and federated data platforms — making them increasingly relevant for digital health and precision public health collaborations.

How they like to work

Exclusively a participant — they have never coordinated an H2020 project, preferring to contribute specialist epidemiological and public health expertise within larger consortia. With 136 unique partners across 30 countries, they maintain a remarkably broad network for an institute of their size, indicating they are a trusted and sought-after partner rather than a project initiator. Their consistent presence in large Research and Innovation Actions (7 of 9 projects) suggests they thrive in ambitious, multi-partner research programmes where their cohort data and analytical capabilities fill a specific niche.

Extensive European network spanning 136 partners across 30 countries, far exceeding what their 9-project portfolio might suggest. This breadth reflects participation in large consortia (often 20+ partners) and positions them as a well-connected node in European public health research.

What sets them apart

Their combination of lifecourse epidemiology, exposome research, and access to Portuguese population cohort data makes them a distinctive partner for any consortium needing Southern European health data alongside analytical expertise. Unlike purely clinical institutes, they bridge population-level evidence with policy-relevant interventions — from childhood obesity to cervical cancer screening equity. Their recent pivot toward FAIR data platforms and AI-driven clinical trials means they can contribute both deep epidemiological knowledge and modern data science capabilities.

Highlights from their portfolio

• UNITE4TB
  Their largest funded project (EUR 616K) combining AI, innovative trial design, and pharmacology for tuberculosis treatment — a significant departure from their traditional epidemiology work.
• ATHLETE
  A flagship exposome project running until 2025 that represents their shift toward environmental exposure science and FAIR data infrastructure for early-life health research.
• RECAP preterm
  Their highest single-project funding (EUR 642K), focused on building a comprehensive European platform for preterm birth research across the lifecourse.